Clinical Advances in Ustekinumab in the Treatment of Crohn's Disease
As the study of inflammatory bowel disease (IBD) advances, various biological agents for IBD are emerging, ushering in a new area of IBD treatment. Ustekinumab, an anti-interleukin-12/23 agent, is a new option for Crohn's disease patients with prior failure of traditional pharmacological tr...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese General Practice Publishing House Co., Ltd
2022-09-01
|
| Series: | Zhongguo quanke yixue |
| Subjects: | |
| Online Access: | https://www.chinagp.net/fileup/1007-9572/PDF/1658996860121-474947965.pdf |